STOCK TITAN
  1. Home
  2. Sec-filings
  3. ABEO
  4. [8-K] ABEONA THERAPEUTICS INC. Reports Material Event

Abeona director Michael Amoroso resigns from board

Abeona Therapeutics Inc. reported that board member Michael Amoroso resigned from its Board of Directors effective June 11, 2026.

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Abeona Therapeutics Inc. reported that board member Michael Amoroso resigned from its Board of Directors effective June 11, 2026. Along with leaving the board, he also stepped down from the Board’s Nominating and Corporate Governance Committee.

The company stated that Mr. Amoroso’s resignation was for personal reasons and was not due to any disagreement with Abeona regarding its operations, policies, or practices. The filing was signed on behalf of the company by Chief Financial Officer Joseph Vazzano.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Board of Directors financial
"resigned as a member of the Board of Directors (the “Board”)"
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
Nominating and Corporate Governance Committee financial
"resigned from the Nominating and Corporate Governance Committee of the Board"
A nominating and corporate governance committee is a group within a company's board of directors responsible for selecting and recommending individuals to serve as company leaders, such as directors or executives. They also develop and oversee policies to ensure the company is run fairly, ethically, and transparently. This committee matters to investors because it helps ensure the company is well-managed and guided by qualified, responsible leadership.
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Section 12(b) of the Act regulatory
"Securities registered pursuant to Section 12(b) of the Act"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Abeona Therapeutics (ABEO) announce about its board on June 11, 2026?
Abeona Therapeutics announced that director Michael Amoroso resigned from its Board of Directors effective June 11, 2026. His departure also includes stepping down from the Nominating and Corporate Governance Committee of the board.

Why did Abeona Therapeutics director Michael Amoroso resign from the board?
The company stated that Michael Amoroso resigned from the board solely for personal reasons. It specifically noted that his resignation did not result from any disagreement with Abeona’s operations, policies, or business practices.

What committee role did Michael Amoroso hold at Abeona Therapeutics before resigning?
Michael Amoroso served on Abeona’s Nominating and Corporate Governance Committee before his resignation. When he left the board effective June 11, 2026, he also resigned from this committee position at the same time.

Who signed the Abeona Therapeutics report regarding the director resignation?
The report regarding Michael Amoroso’s resignation was signed on behalf of Abeona Therapeutics by Joseph Vazzano. He is identified as the company’s Chief Financial Officer and executed the document as a duly authorized officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0000318306 0000318306 2026-06-11 2026-06-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): June 11, 2026

 

ABEONA THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-15771   83-0221517
(State or other jurisdiction   (Commission   (I.R.S. Employer
of incorporation)   File Number)   Identification No.)

 

6555 Carnegie Ave, 4th Floor

Cleveland, OH 44103

(Address of principal executive offices) (Zip Code)

 

(646) 813-4701

(Registrant’s telephone number, including area code)

 

N /A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d 2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Title of Each Class   Trading Symbol   Name of each exchange on which registered
Common Stock, $0.01 par value   ABEO   The Nasdaq Capital Market

 

Securities registered pursuant to Section 12(b) of the Act:

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On June 11, 2026, Michael Amoroso resigned as a member of the Board of Directors (the “Board”) of Abeona Therapeutics Inc. (the “Company”) effective immediately. In connection with his resignation, Mr. Amoroso also resigned from the Nominating and Corporate Governance Committee of the Board on which he served. Mr. Amoroso’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices but solely for personal reasons.

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Abeona Therapeutics Inc.
  (Registrant)
     
  By: /s/ Joseph Vazzano
  Name: Joseph Vazzano
  Title: Chief Financial Officer

 


Date: June 11, 2026

 

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents

Other Documents

Keep reading

More on ABEO

Trending in the feed

Open the live feed